Clinical Trials · NCT02592031
Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Merckle GmbH
- Enrollment
- 49
- Start date
- Feb 2009
- Locations
- See registry
- Primary endpoint
- Comparison of single dose pharmacokinetics (Cmax)